⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

Official Title: Treatment of Delayed Nausea: What Works Best?

Study ID: NCT00020657

Study Description

Brief Summary: RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.

Detailed Description: OBJECTIVES: * Compare the effectiveness of a 5 hydroxytryptamine 3 (5-HT3) receptor antagonist antiemetic vs prochlorperazine in controlling delayed nausea after chemotherapy in patients with chemotherapy-naive cancer. * Compare the effectiveness of prochlorperazine administered on a preventive vs as needed basis in controlling delayed nausea after chemotherapy in these patients. * Compare the quality of life of patients treated with a 5-HT3 receptor antagonist antiemetic vs prochlorperazine. * Compare the quality of life of patients treated with prochlorperazine administered on a preventive vs as needed basis. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center. Patients receive their scheduled chemotherapy regimen containing doxorubicin and their scheduled oral 5 hydroxytryptamine 3 receptor antagonist antiemetic (ondansetron, granisetron, tropisetron, or dolasetron mesylate) combined with dexamethasone on day 1. Patients are then randomized to 1 of 3 antiemetic arms. * Arm I: Patients receive oral prochlorperazine every 8 hours on days 2 and 3. * Arm II: Patients receive oral ondansetron every 12 hours, oral granisetron every 12 hours, or oral dolasetron mesylate either once a day or every 12 hours on days 2 and 3. * Arm III: Patients receive oral prochlorperazine as needed, up to 4 times per day, on days 2 and 3. Quality of life is assessed at baseline and on day 4. PROJECTED ACCRUAL: A total of 670 patients will be accrued for this study within 3 years.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

MBCCOP - Gulf Coast, Mobile, Alabama, United States

CCOP - Western Regional, Arizona, Phoenix, Arizona, United States

CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona, United States

CCOP - Colorado Cancer Research Program, Incorporated, Denver, Colorado, United States

MBCCOP - Hawaii, Honolulu, Hawaii, United States

CCOP - Central Illinois, Decatur, Illinois, United States

CCOP - Wichita, Wichita, Kansas, United States

CCOP - Kalamazoo, Kalamazoo, Michigan, United States

CCOP - Northern New Jersey, Hackensack, New Jersey, United States

CCOP - North Shore University Hospital, Manhasset, New York, United States

CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States

CCOP - Columbus, Columbus, Ohio, United States

CCOP - Dayton, Dayton, Ohio, United States

CCOP - Greenville, Greenville, South Carolina, United States

CCOP - Northwest, Tacoma, Washington, United States

Contact Details

Name: Gary R. Morrow, PhD, MS

Affiliation: James P. Wilmot Cancer Center

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: